Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000097:blood / Q000633:toxicity; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000096:biosynthesis; D003609:Dactinomycin / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D004195:Disease Models, Animal; D005472:Fluorouracil / Q000008:administration & dosage; D006207:Half-Life; D006918:Hydroxyurea / Q000008:administration & dosage; D066298:In Vitro Techniques; D007700:Kinetics; D007939:Leukemia L1210 / Q000188:drug therapy*; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D008938:Mitosis; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D013882:Thiosemicarbazones / Q000008:administration & dosage
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D009607:Nitrosourea Compounds; D013882:Thiosemicarbazones; D003561:Cytarabine; D003609:Dactinomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D005472:Fluorouracil; D006918:Hydroxyurea; D008727:Methotrexate; D003630:Daunorubicin